Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Accured Expenses: 2015-2024

Historic Change in Accured Expenses for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to $10.9 million.

  • UroGen Pharma's Change in Accured Expenses fell 17.69% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 15.82%. This contributed to the annual value of $10.9 million for FY2024, which is 162.17% up from last year.
  • As of FY2024, UroGen Pharma's Change in Accured Expenses stood at $10.9 million, which was up 162.17% from $4.2 million recorded in FY2023.
  • UroGen Pharma's Change in Accured Expenses' 5-year high stood at $10.9 million during FY2024, with a 5-year trough of -$2.6 million in FY2021.
  • Moreover, its 3-year median value for Change in Accured Expenses was $4.2 million (2023), whereas its average is $5.5 million.
  • Per our database at Business Quant, UroGen Pharma's Change in Accured Expenses slumped by 191.66% in 2021 and then spiked by 217.42% in 2023.
  • Over the past 5 years, UroGen Pharma's Change in Accured Expenses (Yearly) stood at $2.8 million in 2020, then slumped by 191.66% to -$2.6 million in 2021, then spiked by 150.23% to $1.3 million in 2022, then surged by 217.42% to $4.2 million in 2023, then spiked by 162.17% to $10.9 million in 2024.